Panobinostat alone did not show any clinical activity. However, when combined with bicalutamide, it extended progression-free survival by 6 months. Combination of panobinostat with docetaxel resulted in a partial response, with a>50% decline in PSA levels, but increased toxicities were observed, with no relevant anti-tumor activity. The results from the panobinostat and external beam radiotherapy study have not been published. The gene discussed is KLK3; the disease is neoplasm.